{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:03:33Z","timestamp":1751774613538,"version":"3.41.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00393-018-0503-9","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T12:31:05Z","timestamp":1531398665000},"page":"776-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue molekulare Mechanismen in der Pathophysiologie der Psoriasisarthritis","Novel molecular mechanisms in the pathophysiology of psoriatic arthritis"],"prefix":"10.1007","volume":"77","author":[{"given":"D.","family":"Simon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kampylafka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Hueber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"issue":"Suppl 2","key":"503_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1468-3083.2009.03565.x","volume":"24","author":"S Prey","year":"2010","unstructured":"Prey S, Paul C, Bronsard V et\u00a0al (2010) Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a\u00a0systematic review of the literature. J\u00a0Eur Acad Dermatol Venereol 24(Suppl 2):31\u201335","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"503_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/acr.23298","volume":"70","author":"D Cretu","year":"2018","unstructured":"Cretu D, Gao L, Liang K et\u00a0al (2018) Differentiating psoriatic arthritis from psoriasis without psoriatic arthritis using novel serum biomarkers. Arthritis Care Res 70:454\u2013461","journal-title":"Arthritis Care Res"},{"key":"503_CR3","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.4049\/jimmunol.1103201","volume":"188","author":"J Lin","year":"2012","unstructured":"Lin J, Zhou Z, Huo R et al (2012) Cyr61 induces IL-6 production by fibroblast-like synoviocytes promoting Th17 differentiation in rheumatoid arthritis. J\u00a0Immunol 188:5776\u20135784","journal-title":"J Immunol"},{"key":"503_CR4","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1002\/art.11287","volume":"48","author":"S Ohshima","year":"2003","unstructured":"Ohshima S, Kuchen S, Seemayer CA et\u00a0al (2003) Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 48:2788\u20132795","journal-title":"Arthritis Rheum"},{"issue":"1","key":"503_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/proteomes6010005","volume":"6","author":"SM Mahendran","year":"2018","unstructured":"Mahendran SM, Chandran V (2018) Exploring the psoriatic arthritis proteome in search of novel biomarkers. Proteomes 6(1):5. https:\/\/doi.org\/10.3390\/proteomes6010005","journal-title":"Proteomes"},{"key":"503_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/696415","author":"C Hansson","year":"2014","unstructured":"Hansson C, Eriksson C, Alenius GM (2014) S\u2011calprotectin (S100A8\/S100A9): a\u00a0potential marker of inflammation in patients with psoriatic arthritis. J\u00a0Immunol Res. https:\/\/doi.org\/10.1155\/2014\/696415","journal-title":"J Immunol Res"},{"key":"503_CR7","first-page":"120","volume":"27","author":"GM Alenius","year":"2009","unstructured":"Alenius GM, Eriksson C, Rantapaa Dahlqvist S (2009) Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol 27:120\u2013123","journal-title":"Clin Exp Rheumatol"},{"key":"503_CR8","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1002\/art.39800","volume":"68","author":"F Abji","year":"2016","unstructured":"Abji F, Pollock RA, Liang K et\u00a0al (2016) Brief report: CXCL10 is a\u00a0possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol 68:2911\u20132916","journal-title":"Arthritis Rheumatol"},{"key":"503_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/1354750X.2016.1278265","volume":"23","author":"R Nisihara","year":"2018","unstructured":"Nisihara R, Skare TL, Zeni JO et\u00a0al (2018) Plasma levels of pentraxin 3 in patients with spondyloarthritis. Biomarkers 23:14\u201317","journal-title":"Biomarkers"},{"key":"503_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13075-017-1417-7","volume":"19","author":"DR Jadon","year":"2017","unstructured":"Jadon DR, Sengupta R, Nightingale A et al (2017) Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a\u00a0prospective cross-sectional comparative study. Arthritis Res Ther 19:210","journal-title":"Arthritis Res Ther"},{"key":"503_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/ard.30.3.213","volume":"30","author":"J Ball","year":"1971","unstructured":"Ball J (1971) Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 30:213\u2013223","journal-title":"Ann Rheum Dis"},{"key":"503_CR12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/acr.23174","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek A, Li S, Chandran V et\u00a0al (2017) Clinical enthesitis in a\u00a0prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis Care Res 69:1685\u20131691","journal-title":"Arthritis Care Res"},{"key":"503_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, Lories RJ, D\u2019Agostino MA et\u00a0al (2017) Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 13:731\u2013741","journal-title":"Nat Rev Rheumatol"},{"key":"503_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","volume":"160","author":"C Johansen","year":"2009","unstructured":"Johansen C, Usher PA, Kjellerup RB et al (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 160:319\u2013324","journal-title":"Br J Dermatol"},{"key":"503_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","volume":"16","author":"LG Baarsen van","year":"2014","unstructured":"van Baarsen LG, Lebre MC, van der Coelen D et al (2014) Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther 16:426","journal-title":"Arthritis Res Ther"},{"key":"503_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T et al (2018) Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a\u00a0randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis 77:523\u2013532","journal-title":"Ann Rheum Dis"},{"key":"503_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2017.1422591","volume":"28","author":"J Bilal","year":"2018","unstructured":"Bilal J, Berlinberg A, Bhattacharjee S et al (2018) A systematic review and meta-analysis of the efficacy and safety of the Interleukin (IL)-12\/23 and IL-17 inhibitors Ustekinumab, Secukinumab, Ixekizumab, Brodalumab, Guselkumab, and Tildrakizumab for the treatment of moderate to severe plaque psoriasis. J\u00a0Dermatolog Treat 28:1\u201310. https:\/\/doi.org\/10.1080\/09546634.2017.1422591","journal-title":"J Dermatolog Treat"},{"key":"503_CR18","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4049\/jimmunol.1300274","volume":"191","author":"SM Paulissen","year":"2013","unstructured":"Paulissen SM, van Hamburg JP, Davelaar N et al (2013) Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase\/prostaglandin E2 pathway, independent of IL-23. J\u00a0Immunol 191:1364\u20131372","journal-title":"J Immunol"},{"key":"503_CR19","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39732","volume":"68","author":"A Reinhardt","year":"2016","unstructured":"Reinhardt A, Yevsa T, Worbs T et al (2016) Interleukin-23-dependent gamma\/delta T cells produce Interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol 68:2476\u20132486","journal-title":"Arthritis Rheumatol"},{"key":"503_CR20","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","volume":"200","author":"A Soare","year":"2018","unstructured":"Soare A, Weber S, Maul L et\u00a0al (2018) Cutting edge: homeostasis of innate lymphoid cells is Imbalanced in psoriatic arthritis. J\u00a0Immunol 200:1249\u20131254","journal-title":"J Immunol"},{"key":"503_CR21","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/art.40150","volume":"69","author":"RJ Cuthbert","year":"2017","unstructured":"Cuthbert RJ, Fragkakis EM, Dunsmuir R et\u00a0al (2017) Brief report: group 3 innate lymphoid cells in human enthesis. Arthritis Rheumatol 69:1816\u20131822","journal-title":"Arthritis Rheumatol"},{"key":"503_CR22","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm.2854","volume":"18","author":"RJ Lories","year":"2012","unstructured":"Lories RJ, McInnes IB (2012) Primed for inflammation: enthesis-resident T cells. Nat Med 18:1018\u20131019","journal-title":"Nat Med"},{"key":"503_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18:1069\u20131076","journal-title":"Nat Med"},{"key":"503_CR24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/annrheumdis-2017-eular.5094","volume":"76","author":"E Kampylafka","year":"2017","unstructured":"Kampylafka E, D\u2019Oliveira I, Linz C et\u00a0al (2017) FRI0625 Improvement of joint inflammation as assessed by MRI and power doppler ultrasound (PDUS) in an open label study in patients with active psoriatic arthritis treated with secukinumab (PSARTROS). Ann Rheum Dis 76:725\u2013726","journal-title":"Ann Rheum Dis"},{"key":"503_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","volume":"45","author":"D Heijde van der","year":"2018","unstructured":"van der Heijde D, Gladman DD, Kishimoto M et al (2018) Efficacy and safety of Ixekizumab in patients with active psoriatic arthritis: 52-week results from a\u00a0phase III study (SPIRIT-P1). J\u00a0Rheumatol 45:367\u2013377","journal-title":"J Rheumatol"},{"key":"503_CR26","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","volume":"56","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Mease PJ, Ritchlin CT et\u00a0al (2017) Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxf) 56:1993\u20132003","journal-title":"Rheumatology (Oxf)"},{"key":"503_CR27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2017-eular.5398","volume":"76","author":"E Araujo","year":"2017","unstructured":"Araujo E, Englbrecht M, Hoepken S et\u00a0al (2017) OP0217 Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PSA patients with active enthesitis \u2013 results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Ann Rheum Dis 76:142\u2013142","journal-title":"Ann Rheum Dis"},{"key":"503_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3899\/jrheum.140647","volume":"42","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ et al (2015) Longterm (52-week) results of a\u00a0phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J\u00a0Rheumatol 42:479\u2013488","journal-title":"J Rheumatol"},{"key":"503_CR29","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","volume":"77","author":"P Nash","year":"2018","unstructured":"Nash P, Ohson K, Walsh J et al (2018) Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a\u00a0phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 77:690\u2013698","journal-title":"Ann Rheum Dis"},{"key":"503_CR30","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","volume":"56","author":"D Heijde van der","year":"2017","unstructured":"van der Heijde D, Dougados M, Landewe R et al (2017) Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4\u2011year outcomes from RAPID-axSpA. Rheumatology (Oxf) 56:1498\u20131509","journal-title":"Rheumatology (Oxf)"},{"key":"503_CR31","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/ng.874","volume":"43","author":"M Matmati","year":"2011","unstructured":"Matmati M, Jacques P, Maelfait J et\u00a0al (2011) A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 43:908\u2013912","journal-title":"Nat Genet"},{"key":"503_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/annrheumdis-2016-209454","volume":"76","author":"K Wilde De","year":"2017","unstructured":"De Wilde K, Martens A, Lambrecht S et\u00a0al (2017) A20 inhibition of STAT1 expression in myeloid cells: a\u00a0novel endogenous regulatory mechanism preventing development of enthesitis. Ann Rheum Dis 76:585\u2013592","journal-title":"Ann Rheum Dis"},{"key":"503_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.311","volume":"41","author":"RP Nair","year":"2009","unstructured":"Nair RP, Duffin KC, Helms C et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199\u2013204","journal-title":"Nat Genet"},{"key":"503_CR34","doi-asserted-by":"publisher","first-page":"e0192010","DOI":"10.1371\/journal.pone.0192010","volume":"13","author":"ND Loft","year":"2018","unstructured":"Loft ND, Skov L, Rasmussen MK et\u00a0al (2018) Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. PLoS ONE 13:e192010","journal-title":"PLoS ONE"},{"key":"503_CR35","doi-asserted-by":"crossref","first-page":"95401","DOI":"10.18632\/oncotarget.20727","volume":"8","author":"R Cascella","year":"2017","unstructured":"Cascella R, Strafella C, Ragazzo M et al (2017) KIF3A and IL-4 are disease-specific biomarkers for psoriatic arthritis susceptibility. Oncotarget 8:95401\u201395411","journal-title":"Oncotarget"},{"key":"503_CR36","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/annrheumdis-2014-206347","volume":"75","author":"D Simon","year":"2016","unstructured":"Simon D, Faustini F, Kleyer A et\u00a0al (2016) Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann Rheum Dis 75:660\u2013666","journal-title":"Ann Rheum Dis"},{"key":"503_CR37","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/jbmr.2521","volume":"30","author":"R Kocijan","year":"2015","unstructured":"Kocijan R, Englbrecht M, Haschka J et\u00a0al (2015) Quantitative and qualitative changes of bone in psoriasis and psoriatic arthritis patients. J\u00a0Bone Miner Res 30:1775\u20131783","journal-title":"J Bone Miner Res"},{"key":"503_CR38","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/annrheumdis-2016-210441","volume":"76","author":"A Ogdie","year":"2017","unstructured":"Ogdie A, Harter L, Shin D et al (2017) The risk of fracture among patients with psoriatic arthritis and psoriasis: a\u00a0population-based study. Ann Rheum Dis 76:882\u2013885","journal-title":"Ann Rheum Dis"},{"key":"503_CR39","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1111\/ijd.13159","volume":"55","author":"TE Amin","year":"2016","unstructured":"Amin TE, ElFar NN, Ghaly NR et al (2016) Serum level of receptor activator of nuclear factor kappa-B ligand in patients with psoriasis. Int J Dermatol 55:e227\u2013e233","journal-title":"Int J Dermatol"},{"key":"503_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-017-0380-2","author":"A Paine","year":"2018","unstructured":"Paine A, Ritchlin C (2018) Altered bone remodeling in psoriatic disease: new insights and future directions. Calcif Tissue Int. https:\/\/doi.org\/10.1007\/s00223-017-0380-2","journal-title":"Calcif Tissue Int"},{"key":"503_CR41","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake S, Udagawa N, Takahashi N et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a\u00a0potent stimulator of osteoclastogenesis. J\u00a0Clin Invest 103:1345\u20131352","journal-title":"J Clin Invest"},{"key":"503_CR42","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/jim-2017-000426","volume":"65","author":"L Zheng","year":"2017","unstructured":"Zheng L, Wang W, Ni J et al (2017) Role of autophagy in tumor necrosis factor-alpha-induced apoptosis of osteoblast cells. J\u00a0Investig Med 65:1014\u20131020","journal-title":"J Investig Med"},{"key":"503_CR43","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/art.20870","volume":"52","author":"TH Kim","year":"2005","unstructured":"Kim TH, Stone M, Payne U et\u00a0al (2005) Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum 52:885\u2013891","journal-title":"Arthritis Rheum"},{"key":"503_CR44","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/ard.2010.138883","volume":"70","author":"SJ Pedersen","year":"2011","unstructured":"Pedersen SJ, Sorensen IJ, Garnero P et\u00a0al (2011) ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors. Ann Rheum Dis 70:1375\u20131381","journal-title":"Ann Rheum Dis"},{"key":"503_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-016-1040-z","volume":"18","author":"NS Gudmann","year":"2016","unstructured":"Gudmann NS, Munk HL, Christensen AF et\u00a0al (2016) Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis. Arthritis Res Ther 18:141","journal-title":"Arthritis Res Ther"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0503-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0503-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T19:08:44Z","timestamp":1751742524000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0503-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0503-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2018,7,12]]},"assertion":[{"value":"12 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Simon, E.\u00a0Kampylafka und A.J.\u00a0Hueber geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}